Chimeric immunoreceptor useful in treating human cancers

Patent metadata

Field	Value
Publication number	US-11278594-B2
Application number	US-201916723782-A
Country	US
Kind code	B2
Filing date	Dec 20, 2019
Priority date	Apr 30, 2001
Publication date	Mar 22, 2022
Grant date	Mar 22, 2022

Abstract

The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human malignancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targeting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.

First claim

The invention claimed is:

1. A chimeric immunoreceptor which consists of SEQ ID NO:17.

2. A plasmid which expresses the chimeric immunoreceptor of claim 1 .

3. The plasmid of claim 2 which is SEQ ID NO:24.

4. A T cell which expresses the chimeric immunoreceptor of claim 1 .

5. A method of treating an IL13α2 receptor-expressing cancer in a patient in need thereof, which comprises administering to said patient a chimeric immunoreceptor of claim 1 .

6. A method of claim 5 wherein said IL13α2 receptor-expressing cancer is a glioma.

7. A method of treating an IL13α2 receptor-expressing cancer in a patient in need thereof, which comprises administering to said patient a T cell of claim 4 .

8. A method of claim 7 wherein said IL13α2 receptor-expressing cancer is a glioma.

Assignees

• Hope City

Inventors

• Jensen Michael

Classifications

• A61K40/4221

  CD20 · CPC title

• A61K40/4217

  Receptors for interleukins [IL] · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title